215 related articles for article (PubMed ID: 17320115)
21. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
Shi V; Tridane A; Kuang Y
J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195
[TBL] [Abstract][Full Text] [Related]
22. Forgiveness of non-adherence to HIV-1 antiretroviral therapy.
Shuter J
J Antimicrob Chemother; 2008 Apr; 61(4):769-73. PubMed ID: 18256112
[TBL] [Abstract][Full Text] [Related]
23. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects.
Smith RJ; Wahl LM
Bull Math Biol; 2005 Jul; 67(4):783-813. PubMed ID: 15893553
[TBL] [Abstract][Full Text] [Related]
24. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d'Ivoire.
Diabaté S; Alary M; Koffi CK
AIDS; 2007 Aug; 21(13):1799-803. PubMed ID: 17690579
[TBL] [Abstract][Full Text] [Related]
25. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.
Macalino GE; Hogan JW; Mitty JA; Bazerman LB; Delong AK; Loewenthal H; Caliendo AM; Flanigan TP
AIDS; 2007 Jul; 21(11):1473-7. PubMed ID: 17589194
[TBL] [Abstract][Full Text] [Related]
26. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
[No Abstract] [Full Text] [Related]
27. [Progress and problems of the treatment of HIV infection].
Carosi G; Torti C; Petroni A
Minerva Ginecol; 2000 Dec; 52(12 Suppl 1):38-53. PubMed ID: 11526688
[TBL] [Abstract][Full Text] [Related]
28. Impact of resistance to antiretroviral therapy in the minority community.
Rodriguez AE; Campo RE; Gathe JC; Kwakwa HA
AIDS Read; 2004 Oct; 14(10 Suppl):S9-11. PubMed ID: 15497217
[TBL] [Abstract][Full Text] [Related]
29. Adherence, resistance, and timing: current issues in the use of new therapies.
Volberding P
AIDS Read; 2002 Aug; 12(8):349-50, 356-7, 368. PubMed ID: 12229892
[TBL] [Abstract][Full Text] [Related]
30. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
31. Why do patients fail HIV therapy?
Waters L; Nelson M
Int J Clin Pract; 2007 Jun; 61(6):983-90. PubMed ID: 17504360
[TBL] [Abstract][Full Text] [Related]
32. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
33. Measuring HIV treatment adherence in clinical practice.
Hecht FM
AIDS Clin Care; 1998 Aug; 10(8):57-9. PubMed ID: 11365682
[TBL] [Abstract][Full Text] [Related]
34. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
35. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.
Glass TR; De Geest S; Hirschel B; Battegay M; Furrer H; Covassini M; Vernazza PL; Bernasconi E; Rickenboch M; Weber R; Bucher HC;
Antivir Ther; 2008; 13(1):77-85. PubMed ID: 18389901
[TBL] [Abstract][Full Text] [Related]
36. Antiviral adherence dilemmas.
Roland ME
Focus; 1998 Feb; 13(3):1-4. PubMed ID: 11365167
[TBL] [Abstract][Full Text] [Related]
37. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
Lagnese M; Daar ES
Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
[TBL] [Abstract][Full Text] [Related]
38. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.
Bruno CJ; Jacobson JM
J Antimicrob Chemother; 2010 Sep; 65(9):1839-41. PubMed ID: 20639524
[TBL] [Abstract][Full Text] [Related]
39. The development of artificial neural networks to predict virological response to combination HIV therapy.
Larder B; Wang D; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; Monforte AD; Torti C; Zazzi M; Lane C
Antivir Ther; 2007; 12(1):15-24. PubMed ID: 17503743
[TBL] [Abstract][Full Text] [Related]
40. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana.
Vriesendorp R; Cohen A; Kristanto P; Vrijens B; Rakesh P; Anand B; Iwebor HU; Stiekema J
Eur J Clin Pharmacol; 2007 Dec; 63(12):1115-21. PubMed ID: 17882408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
